NAPSRx News: Allergan will acquire KYTHERA Biopharmaceuticals

WASHINGTON - June 17, 2015 - PRLog -- Allergan plc has agreed to acquire KYTHERA Biopharmaceuticals, Inc for approximately $2.1 billion valued at $75 per KYTHERA share. Allergan is expected to gain access to Kythera’s prescription portfolio which includes their lead product KYBELLA, the first and only approved non-surgical treatment for reduction of submental fullness. KYBELLA™ was approved on April 29, 2015 and is subject to regulatory approval in Switzerland, Canada and Australia.  This acquisition will certainly compliment Allergan’s current portfolio further strengthening their presence in the aesthetic medicine market. Allergan will also acquire setipiprant (KYTH-105) a novel compound currently being developed by Kythera for the prevention of male pattern baldness.

"The acquisition of KYTHERA is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth," said Brent Saunders, CEO and President of Allergan.  "KYBELLA™ is an exciting new product that offers patients the first and only clinically-proven, non-surgical treatment for submental fullness (excess fat under the chin). As a leader in aesthetics, we know our customers are looking to offer their patients new options beyond traditional facial aesthetics. KYBELLA™ will do that while complementing our market leading facial aesthetics portfolio, which includes BOTOX®, JUVEDERM® XC, JUVEDERM VOLUMA® XC, LATISSE® and SKINMEDICA.  KYBELLA™ is also a pivotal entry point for expanding the use of facial aesthetic products in men, while KYTHERA's setipiprant (hair-loss) development program can drive additional long-term value."

Allergan's acquisition of KYTHERA is pending approval by the shareholders of KYTHERA in accordance with the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and subject to customary closing conditions. The transaction is expected to close by the third quarter of 2015.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

Allergan's acquisiton of Kythera will further foritify the company's robust aesthetic pipeline. This will without a doubt bolster the need for both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they prefer individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.